Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP649245.RASwYpmOTMki0chTtyfmY1HzgPdNtK9K8lLA_0OHDFGl4130_assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP649245.RASwYpmOTMki0chTtyfmY1HzgPdNtK9K8lLA_0OHDFGl4130_provenance.
• NP277614.RA1uMT4oIif94q5VLYYLRGX1Nd7WRpHEs-gpf343tnxQg130_assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP277614.RA1uMT4oIif94q5VLYYLRGX1Nd7WRpHEs-gpf343tnxQg130_provenance.
• NP576910.RAlKkS39Mzcuq2BCSvy1iTjsRSDwNtNXD85MR3PL5k7lI130_assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP576910.RAlKkS39Mzcuq2BCSvy1iTjsRSDwNtNXD85MR3PL5k7lI130_provenance.
• NP754660.RAonZQALD4iEb4CCZEbaTymBnTd8U7Xfxf-WI_8JihVLM130_assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP754660.RAonZQALD4iEb4CCZEbaTymBnTd8U7Xfxf-WI_8JihVLM130_provenance.
• NP375580.RAMuer0r1cXeZr8H41xTqNOLKVX9V3t8EYGq892Pdu7wc130_assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP375580.RAMuer0r1cXeZr8H41xTqNOLKVX9V3t8EYGq892Pdu7wc130_provenance.
• NP745923.RAOlTseHxV7U_qSUH8bd9JEu55vsdt0TOTp0DL42GyO3s130_assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP745923.RAOlTseHxV7U_qSUH8bd9JEu55vsdt0TOTp0DL42GyO3s130_provenance.
• NP913648.RA6TOl69fm9odiIIN0JNcFRc3V3mO-IxmSaKsp82an3FU130_assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP913648.RA6TOl69fm9odiIIN0JNcFRc3V3mO-IxmSaKsp82an3FU130_provenance.
• NP1005725.RAArIUz8OkjzAFOIjVZ_KRNDdsCiG9jOvffrUx66yoGOU130_assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005725.RAArIUz8OkjzAFOIjVZ_KRNDdsCiG9jOvffrUx66yoGOU130_provenance.
• assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1005724.RAZtYBay8Eg2bKXRfIHspEs_cBLe6QxjgVXsqnruHeA6U130_assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005724.RAZtYBay8Eg2bKXRfIHspEs_cBLe6QxjgVXsqnruHeA6U130_provenance.
• assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP810151.RAFm6w1KwWceVJnWirD3MSC6lrZKMI0egK7pJnOdnPOqI130_assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP810151.RAFm6w1KwWceVJnWirD3MSC6lrZKMI0egK7pJnOdnPOqI130_provenance.
• assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1005723.RAG2w1qb-AUwt6Up_vygcPJ5u--a6jFlsyYk5U26UD2Fw130_assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1005723.RAG2w1qb-AUwt6Up_vygcPJ5u--a6jFlsyYk5U26UD2Fw130_provenance.
• NP337069.RAkmtZvBoX6ep3JUd2JneXcgaSs-PaZcJY0TNfmSJDSMQ130_assertion description "[Our studies demonstrate that inhibitors of autophagy or cathepsin B activity and/or molecular targeting of p62/SQSTM1, Atg7, or cathepsin B result in partial reversal of the suppressive effects of AS(2)O(3) on BCR-ABL expressing leukemic progenitors, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP337069.RAkmtZvBoX6ep3JUd2JneXcgaSs-PaZcJY0TNfmSJDSMQ130_provenance.